ICD-10 Specific code E65: Localized adiposity
Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
Translations
| Language | Translation |
|---|---|
English
|
Localized adiposity |
French
|
Adiposité localisée |
Hierarchical position
| Level | Code | Title | |
|---|---|---|---|
| 1 | IV | Endocrine, nutritional and metabolic diseases | |
| 2 | E65-E68 | Obesity and other hyperalimentation | |
| 3 | E65 | Localized adiposity |
Indicated medicines
| Active Ingredient |
|---|
|
Liraglutide is a GLP-1 analogue with 97% sequence homology to human GLP-1 that binds to and activates the GLP-1 receptor. The GLP-1 receptor is the target for native GLP-1, an endogenous incretin hormone that potentiates glucose-dependent insulin secretion from the pancreatic beta cells. Unlike native GLP-1, liraglutide has a pharmacokinetic and pharmacodynamic profile in humans suitable for once daily administration. |
|
Orlistat is a potent, specific and long-acting inhibitor of gastrointestinal lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine site of the gastric and pancreatic lipases. The inactivated enzyme is thus unavailable to hydrolyse dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. |